A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis

Radiotherapy and Oncology

Volumn 103, Issue 1, 2012, Pages 25-31

  Terashima, Kazuki ^a   Demizu, Yusuke ^a   Hashimoto, Naoki ^a   Jin, Dongcun ^a   Mima, Masayuki ^a   Fujii, Osamu ^a   Niwa, Yasue ^a   Takatori, Kento ^b   Kitajima, Naoto ^b   Sirakawa, Sachiyo ^c   Yonson, Ku ^c   Hishikawa, Yoshio ^a   Abe, Mitsuyuki ^a   Sasaki, Ryohei ^c   Sugimura, Kazuro ^c   Murakami, Masao ^a  

^a HYOGO ION BEAM MEDICAL CENTER   (Japan)

^b Kasai City Hospital   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiotherapy; Gemcitabine; Locally advanced; Pancreatic cancer; Proton radiotherapy

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON THERAPY; RADIATION DOSE FRACTIONATION; SIDE EFFECT; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMORADIOTHERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROTONS;

EID: 84859710746     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.12.029     Document Type: Article

References (29)

1. Burris 3rd HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
2. Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54:385-7. (Pubitemid 40299095)
3. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34. (Pubitemid 24209062)
4. D'Souza MA, Shrikhande SV. Pancreatic resectional surgery: an evidence-based perspective. J Cancer Res Ther 2008;4:77-83.
5. Galloway NR, Aspe JR, Sellers C, Wall NR. Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer. Pancreas 2009;38:782-90.
6. GITSG. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751-5.
7. Huang PI, Chao Y, Li CP, et al. Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2009;73:159-65.
8. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001;91:490-5. (Pubitemid 32105694)
9. Ishii H, Furuse J, Boku N, et al. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol 2010;40:573-9.
10. Iwata H, Murakami M, Demizu Y, et al. High-dose proton therapy and carbonion therapy for stage I nonsmall cell lung cancer. Cancer 2010;116:2476-85.
11. Kagawa K, Murakami M, Hishikawa Y, et al. Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center. Int J Radiat Oncol Biol Phys 2002;54:928-38.
12. Kamigaki T, Murakami M, Matsumoto IMM. A phase I study of proton beam therapy for locally advanced pancreatic cancer: analysis of feasibility and antitumor effect. J Clin Oncol 2008;26 [May 20 Suppl.; abstr 15675) 2008].
13. Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010;76:S101-7.
14. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010;76:S42-9.
15. Komatsu S, Fukumoto T, Demizu Y, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011.
16. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS. Radiosensitization by gemcitabine. Oncology (Williston Park) 1999;13:55-60.
17. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;57:98-104. (Pubitemid 36959744)
18. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-10. (Pubitemid 11022870)
19. Morganti AG, Valentini V, Macchia G, et al. 5-Fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: phase I-II dose-escalation study. Int J Radiat Oncol Biol Phys 2004;59:1454-60. (Pubitemid 38954068)
20. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801-8. (Pubitemid 46818734)
21. Nishimura H, Ogino T, Kawashima M, et al. Proton-beam therapy for olfactory neuroblastoma. Int J Radiat Oncol Biol Phys 2007;68:758-62. (Pubitemid 46818736)
22. Okusaka T, Ito Y, Ueno H, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004;91:673-7. (Pubitemid 39141622)
23. Ozaki H, Hiraoka T, Mizumoto R, et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999;29:16-22. (Pubitemid 29058554)
24. Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, et al. Eastern Cooperative Oncology Group. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008;26 [May 20 Suppl.; abstr 4506].
25. Schulz.-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007;25:953-64.
26. Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;53:146-50. (Pubitemid 34465818)
27. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.
28. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-20.
29. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 2008;37:269-74.